Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.

G Ransmayr, G Künig, M Neubauer, M Wagner, M Falk
{"title":"Effect of age and disease duration on parkinsonian motor scores under levodopa therapy.","authors":"G Ransmayr,&nbsp;G Künig,&nbsp;M Neubauer,&nbsp;M Wagner,&nbsp;M Falk","doi":"10.1007/BF02259659","DOIUrl":null,"url":null,"abstract":"<p><p>One hundred and fifty patients suffering from Parkinson's disease were analysed for the expression of the motor symptoms during optimum response to levodopa therapy (subscale III of the Unified-Parkinson's Disease Rating Scale). Patients were grouped according to age (< or = 64, 65-74, > or = 75 years). Disease duration and daily levodopa dosage were similar in the three groups. Pooled residual scores for posture and gait impairment (PGI), tremor (T), rigidity (R) and distal motor impairment (DMI; hand and foot movements) increased with age (Kruskal-Wallis ANOVA). The parkinsonian scores were significantly higher than the scores of 150 age-matched normal controls (Mann-Whitney U test). The differences between the patients' scores and the scores of the age-matched controls increased with age. In spite of a significant increase in the daily levodopa dosage with disease duration (linear regression), PGI aggravated age-dependently, and DMI age-independently with symptom duration (Spearman rank correlation). In contrast, T and R did not increase with disease duration.</p>","PeriodicalId":16466,"journal":{"name":"Journal of Neural Transmission - Parkinson's Disease and Dementia Section","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02259659","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neural Transmission - Parkinson's Disease and Dementia Section","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02259659","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

One hundred and fifty patients suffering from Parkinson's disease were analysed for the expression of the motor symptoms during optimum response to levodopa therapy (subscale III of the Unified-Parkinson's Disease Rating Scale). Patients were grouped according to age (< or = 64, 65-74, > or = 75 years). Disease duration and daily levodopa dosage were similar in the three groups. Pooled residual scores for posture and gait impairment (PGI), tremor (T), rigidity (R) and distal motor impairment (DMI; hand and foot movements) increased with age (Kruskal-Wallis ANOVA). The parkinsonian scores were significantly higher than the scores of 150 age-matched normal controls (Mann-Whitney U test). The differences between the patients' scores and the scores of the age-matched controls increased with age. In spite of a significant increase in the daily levodopa dosage with disease duration (linear regression), PGI aggravated age-dependently, and DMI age-independently with symptom duration (Spearman rank correlation). In contrast, T and R did not increase with disease duration.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
年龄和病程对左旋多巴治疗帕金森运动评分的影响。
我们分析了150名帕金森病患者在左旋多巴治疗最佳反应期间的运动症状表达(统一帕金森病评定量表的亚量表III)。患者按年龄分组(<或= 64岁,65-74岁,>或= 75岁)。三组患者病程及日左旋多巴用量相似。姿势和步态障碍(PGI)、震颤(T)、僵硬(R)和远端运动障碍(DMI)的汇总残差评分;手和脚的运动)随年龄增加而增加(Kruskal-Wallis方差分析)。帕金森得分明显高于150名年龄匹配的正常对照(Mann-Whitney U检验)。随着年龄的增长,患者的得分与年龄匹配的对照组的得分之间的差异越来越大。尽管每日左旋多巴剂量随疾病持续时间显著增加(线性回归),PGI加重与年龄相关,DMI加重与症状持续时间无关(Spearman秩相关)。相比之下,T和R不随病程的延长而增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Fibroblast growth factors: structure-activity on dopamine neurons in vitro. Injection of a minuscule dose of FeCl3 within the ventrolateral striatum causes a chronic disturbance of the integrative function within the limbic part of the ventral striatum. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid. PET imaging of neocortical monoaminergic terminals in Parkinson's disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1